Follicular Lymphoma | Clinical

August 23, 2021

Enrollment in the phase 2b PARADIGME trial of 177Lu lilotomab satetraxetan (Betalutin) in patients with follicular lymphoma has continued despite the surge of the COVID-19 Delta variant.

August 23, 2021

The first patient has been dosed in a trial of FHD-609, a selective protein degrader of bromodomain-containing protein 9, for the treatment of synovial sarcoma.

August 12, 2021

The first patient with marginal zone lymphoma has been dosed in the global phase 2 TIDAL study of zandelisib, a phosphatidylinositol 3-kinase (PI3K) delta inhibitor, for the treatment of MZL and follicular lymphoma in patients who have received at least 2 or more prior therapies.

August 10, 2021

Sattva S. Neelapu, MD, discusses the challenges surrounding chimeric antigen receptor T-cell therapy for the treatment of follicular lymphoma and other lymphomas.

July 28, 2021

Dr Perry Cook discusses the challenges of treating relapsed/refractory follicular lymphoma in later lines and describes ongoing developments in the treatment landscape.

July 28, 2021

A hematologist/oncologist provides insights on individualizing second-line therapy for patients with relapsed/refractory follicular lymphoma.

July 28, 2021

Perry Cook, MD, reviews the role of molecular testing and biomarkers in treatment selection in patients with follicular lymphoma.

July 28, 2021

A hematologist/oncologist discusses the tazemetostat as a treatment option for patients with relapsed/refractory follicular lymphoma.

July 28, 2021

A key opinion leader explains the first-line treatment options for follicular lymphoma and the challenges of treating patients with early disease progression.

July 28, 2021

Perry Cook, MD, presents the case of a 76-year-old man with relapsed/refractory follicular lymphoma.